*EIBALL Subcommittee*

Mission Statement:

To facilitate imaging biomarker development, standardization and promote their use in clinical trials and in clinical practice by collaboration with specialist societies, international standards agencies and trials organizations to develop a network of excellence.

2 year roadmap for EIBALL

PILLAR 1 - *Establish*	PILLAR 2 - *Standardize*	PILLAR 3 - *Educate*
Establishing a functional biomarker profile that is current and relevant	Enabling clinical use of biomarkers by setting standards for data acquisition and image processing	Education on appropriate use of functional imaging biomarkers and their interpretation
On-line inventory of biomarkers available, and how to make the measurements	Set standards for reporting, use of absolute values vs. functional volumes of biomarkers above or below 95%CI of reproducibility	Plan 2 workshops pa, embedded within partner organizations (e.g EORTC/EGAM or RSNA/ISMRM, ESHI)
Action: Partner with members of EORTC who liaise with disease oriented groups to establish inventory	*Action:* Work with QIBA to enable reporting standards Commence initiative to develop thresholds for combined biomarkers	*Action:* Discuss possibility of this with organizing committees of these meetings

OUTPUT

	PILLAR 1	PILLAR 2	PILLAR 3
Yr 1	Develop on-line inventory	Establish validity of functional volumes as robust biomarkers	Plan work-shops for 2019/2020
Yr 2	On-line inventory available to partners	Manuscript on functional biomarkers as decision-support tools	Delivery of workshops, engagement of young investigators

Tasks to take forward 2 years and beyond:

1. Inventory (with EORTC)
2. Establish standards and methods for ASL
3. Establish standards and methods for MRF biomarkers
4. Establish standards and methods for radiomic biomarkers
5. Establish methods/SOP for centre accreditation in MRI
6. Liaise with ESHI re educational workshop
7. Set up forum at EORTC EGAM for EIBALL participation
8. Work with QIBA on protocols and ink to inventory
9. Discussion group regarding biomarker thresholds and how we should develop this
10. Discussion group on how we should "bank" biomarker data for future use